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ABSTRACT 
 
Cellular prion protein, PrPC, undergoes pathogenic structural conversion into the proteinase K 
(PK)-resistant isoform, PrPSc, to constitute a nucleic acid-free infectious agent, so called a 
prion. To determine whether a recently identified PrP-like protein, named PrPLP/Dpl, could 
also be transformed to a prion-like protein, we intracerebrally inoculated a mouse-adapted 
Fukuoka-1 prion into Ngsk and Zrch I mice either homozygously (Prnp0/0) or heterozygously 
(Prnp0/+) devoid of PrPC. Only the former expressed PrPLP/Dpl ectopically in the brains, 
particularly in neurons. Ngsk Prnp0/+ and Zrch I Prnp0/+ mice similarly developed the disease. 
The diseased Ngsk Prnp0/+ mice transmitted the disease to the mice expressing PrPC but not to 
the mice expressing PrPLP/Dpl, showing abundant accumulation of PrPSc but not PK-resistant 
PrPLP/Dpl in the brains. Moreover, the inoculated Ngsk Prnp0/0 mice neither developed the 
disease nor produced any infectivity transmissible to PrPLP/Dpl-expressing mice. These 
results indicate that PrPLP/Dpl have no potential to undergo pathogenic conversion to form a 
prion-like infectious particle. 
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INTRODUCTION 
 
Transmissible spongiform encephalopathies, 
or prion diseases including Creutzfeldt-Jakob 
disease in humans and scrapie in animals, are 
infectious neurodegenerative disorders 
characterized by deposition of an abnormally 
folded, proteinase K (PK)-resistant isoform 
of prion protein, PrPSc, in the central nervous 
system (Prusiner, 1998). PrPSc is a highly 
fibrinogenic protein generated by the 
structural conversion of the normal 
PK-sensitive PrP (PrPC), a 
glycosylphosphatidylinositol (GPI)-anchored 
membrane glycoprotein abundantly 
expressed by neurons (Prusiner, 1998). Mice 
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devoid of PrPC (Prnp0/0) were resistant to the 
diseases without accumulation of PrPSc or 
propagation of infectious agents, or prions, in 
the brain (Bueler et al., 1993, Prusiner et al., 
1993, Sakaguchi et al., 1995), strongly 
arguing for the “protein-only” hypothesis 
(Prusiner, 1998). This hypothesis postulates 
that a prion is mainly composed of PrPSc and 
propagates via the pathogenic conversion of 
PrPC into PrPSc (Prusiner, 1998). 
Intermolecular interaction of these two 
molecules is thought to be essential in the 
conversion (Prusiner, 1998). 
 
The gene designated Prnd encoding a 
PrP-like protein, PrPLP/Doppel (Dpl), was 
recently identified 16 kb downstream of the 
murine PrP gene, Prnp (Li et al., 2000, 
Moore et al., 1999). PrPLP/Dpl is also a 
GPI-anchored glycoprotein of the raft 
membrane and shares 23% identical amino 
acids with PrP (Li et al., 2000, Moore et al., 
1999). Its protein structure is also extremely 
similar to that of the C-terminal two-third of 
PrPC, comprising three α-helices and two 
short β-strands (Mo et al., 2001). These 
topological and structural similarities of the 
two proteins raised the question of whether 
PrPLP/Dpl could modify the pathogenesis of 
prion diseases by interfering with the 
interaction between PrPC and PrPSc. Moore et 
al. and Tuzi et al. recently showed that 
PrPLP/Dpl had no potential to affect 
pathogenesis by demonstrating that mice 
expressing PrPLP/Dpl ectopically in the 
brains developed the disease with incubation 
periods and pathologies indistinguishable 
from those in control mice (Moore et al., 
2001, Tuzi et al., 2002). However, another 
intriguing question remains to be addressed, 
that is, whether PrPLP/Dpl itself can undergo 
pathogenic conversion and become an 
infectious isoform that can propagate like a 
prion. 
 
In the present study, we inoculated a 
mouse-adapted Fukuoka-1 prion into Ngsk 
Prnp0/0 and Ngsk Prnp0/+ mice, both 
ectopically expressing PrPLP/Dpl in the 
brain due to an unusual intergenic RNA 
splicing conducted on the Ngsk targeted 
allele (Li et al., 2000), and then examined 
whether PrPLP/Dpl-associated infectivity 
could be generated in these mice by 
inoculating the brain homogenates of these 
mice into Ngsk Prnp0/0 mice expressing 
PrPLP/Dpl only. 
 
MATERIALS AND METHODS 
 
Mice 
C57BL/6 mice were purchased from Japan 
SLC. Ngsk Prnp0/0 and Zrch I Prnp0/0 mice 
were generated as previously described 
(Bueler et al., 1992, Sakaguchi et al., 1995). 
To produce Ngsk Prnp0/+ and Zrch I Prnp0/+ 
mice, Ngsk Prnp0/0 and Zrch I Prnp0/0 mice 
were intercrossed with C57BL/6 mice, 
respectively. The mice were handled in 
accordance with the Guidelines of Animal 
Experimentation of Nagasaki University. 
 
Prion Inoculation 
10% (w/v) brain homogenates of mice 
suffering from terminal disease after 
inoculation of a Fukuoka-1 prion (kindly 
provided by Dr. Tateishi) were prepared in 
phosphate-buffered saline (PBS), and an 
aliquot (20 µl) of the homogenates was 
intracerebrally inoculated into each mouse 
under anesthetization by the inhalation of 
diethyl ether (Wako Pure Chemical Industries, 
Ltd., Osaka, Japan). 
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Western Blotting 
Total proteins extracted from mouse brains in 
a buffer (50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 0.5% Nonidet P-40, 0.5% sodium 
deoxycholate, 1 mM EDTA) were treated 
with or without 20 µg/ml PK (Wako Pure 
Chemical Industries) at 37˚C for 30 min, and 
then boiled in the presence of Laemmli’s 
buffer for 10 min to halt the PK digestion. 
The proteins were separated on 12% 
SDS-polyacrylamide gel and electrically 
transferred onto a nitrocellulose membrane 
(Millipore Corporation, Bedford, MA). After 
1 hr blocking at room temperature (RT) in 
TBST (10 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 0.1% Tween-20) containing 5% dry 
skim milk, the membrane was incubated with 
an indicated first antibody in TBST 
containing 1% dry skim milk for 2 hr at RT. 
Anti-PrP and anti-PrPLP/Dpl sera were 
raised against recombinant mouse PrP23-231 
in Ngsk Prnp0/0 mice and recombinant mouse 
PrPLP/Dpl24-154 in rabbit, respectively. The 
immunocomplexes were detected by using 
horseradish peroxidase-conjugated antibodies 
(Amersham Pharmacia Biotech, 
Buckinghamshire, UK) and an ECL system 
(Amersham Pharmacia Biotech). 
 
Immunohistochemistry 
Deparaffinized sections were digested with 1 
mg/ml trypsin for 15 min at 37˚C, and then 
placed in 3% H2O2 in methanol for 30 min at 
room temperature to eliminate endogenous 
peroxidase activity. After treatment with 
normal rabbit serum for 30 min, the tissue 
sections were incubated overnight at 4˚C 
with anti-GFAP (1:50 [Dako, Kyoto, Japan]). 
To detect the glial fibrillary acidic protein 
(GFAP) immunoreactivity, we used the 
Polymer-Immuno Complex method in 
accordance with the manufacturer's 
recommendations (Dako). The 
antibody-bound peroxidase was revealed 
with 0.04 % diamino-benzidine (Sigma 
Chemical Co., St. Louis, MO). 
 
RESULTS 
 
A mouse-adapted Fukuoka-1 prion was 
inoculated intracerebrally into Ngsk Prnp0/0, 
Ngsk Prnp0/+, and Zrch I Prnp0/+ mice. The 
former two mouse lines expressed PrPLP/Dpl 
in the brains, particularly in neurons, but the 
latter did not (Li et al., 2000). In keeping 
with our previous report (Sakaguchi et al., 
1995), none of the Ngsk Prnp0/0 mice 
exhibited the disease-specific neurological 
symptoms for up to 600 days 
post-inoculation (p.i.) (Table 1). By contrast, 
all of the Ngsk Prnp0/+ and Zrch I Prnp0/+ 
mice developed the disease with similar 
incubation times of 282.3±22.5 and 
286.4±27.0 days p.i., respectively (Table 1), 
and with similar clinical symptoms such as 
body weight loss, greasy yellowish hair, 
kyphosis, and flaccid paralysis of legs. 
Comparable levels of PrPSc with the same 
patterns of glycosylation were detected in the 
brains of these diseased mice on Western 
blotting (Figure 1). Histological findings in 
the affected brain tissues were also 
indistinguishable between the two lines of 
mice: the brains were markedly atrophic 
(data not shown) and many vacuoles were 
detectable mainly in the cerebral cortex and 
hippocampus (Figure 2, upper panels). 
Moreover, hypertrophic astrocytes with 
strong immunoreactivities of GFAP were 
similarly infiltrated in the same brain regions 
of these mice on immunohistochemical 
examinations (Figure 2, lower panels).
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Figure 1: Western blotting of the brains of Ngsk Prnp0/+ and Zrch I Prnp0/+ mice with 
neurological symptoms and of Ngsk Prnp0/0 mice 360 days after inoculation with the 
Fukuoka-1 prion. The brain homogenates treated with (+) or without (-) proteinase K 
(PK) were probed by rabbit antiserum against recombinant mouse PrPLP/Dpl, mouse 
antiserum against recombinant mouse PrP, and mouse monoclonal antibody against 
rabbit glyceraldehyde-3-phosphate dehydrogenase (GAPDH; HyTest, Turku, 
Finland). 
 
PrPC undergoes conformational conversion 
into a PK-resistant PrP, PrPSc, and mediates 
the prion transmission. It has been suggested 
that PrPC is also converted into a 
PK-sensitive but infectious intermediate form 
of PrP, termed PrP*, and that it supports the 
prion propagation (Aguzzi and Weissmann, 
1997). To determine whether PrPLP/Dpl 
could be similarly transformed into a 
PK-resistant or a PK-sensitive but infectious 
intermediate isoform, we first subjected the 
brains of both the diseased Ngsk Prnp0/+ and 
the Ngsk Prnp0/0 mice sacrificed at 360 days 
p.i. to Western blotting. On Western blotting, 
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anti-PrP antibodies detected PK-resistant 
PrPSc abundantly accumulated in the brains 
of Ngsk Prnp0/+ mice (Figure 1), but not in 
the Ngsk Prnp0/0 mice (data not shown). By 
contrast, the PrPLP/Dpl detectable in the 
brains of these mice by anti-PrPLP/Dpl 
antibodies raised against recombinant mouse 
PrPLP/Dpl in rabbit was digested to an 
undetectable level by the PK treatment 
(Figure 1). 
Ngsk Prnp0/+ Zrch I Prnp0/+
HE
GFAP
 
 
Figure 2: Hematoxylin-eosin staining (upper panel) and GFAP immunohistochemical 
staining (lower panel) of the brains of Ngsk Prnp0/+ and Zrch I Prnp0/+ mice with 
neurological symptoms after inoculation with the Fukuoka-1 prion. (Magnification, 
×12.5; Inset magnification, ×50). 
 
We next inoculated the brain homogenate of 
the diseased Ngsk Prnp0/+ mice 
intracerebrally into wild-type, Ngsk Prnp0/+ 
and Ngsk Prnp0/0 mice to determine whether 
PrPLP/Dpl could be converted into a 
prion-like infectious protein. All of the 
wild-type and Ngsk Prnp0/+ mice developed 
the disease at 161±11 and 269±27 days p.i., 
respectively (Table 1). The clinical symptoms 
in these mice were indistinguishable from 
those of the corresponding mice inoculated 
by the brain homogenates of infected 
wild-type mice (data not shown). By contrast, 
none of the Ngsk Prnp0/0 mice exhibited 
disease-specific symptoms for up to 600 days 
p.i. (Table 1). Additionally, we inoculated the 
brain homogenate from the Ngsk Prnp0/0 
mice sacrificed at 112 weeks p.i. into 
indicator Ngsk Prnp0/0 mice. However, no 
disease-specific neurological symptoms 
could be detected in the indicator mice for up 
to 600 days p.i. (Table 1). 
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Table 1. No PrPLP/Dpl-associated infectivity in Ngsk Prnp0/+ and Ngsk Prnp0/0 mice 
donor mouse recipient mouse
diseased mice
/inoculated mice
incubation time 
(mean±SE; days)
wild-type 
(diseased)
Ngsk Prnp0/+ 5/5 282.3±22.5
Zrch I Prnp0/+ 5/5 286.4±27.0
wild-type 7/7 161.4±10.9
Ngsk Prnp0/+ 
(diseased) Ngsk Prnp
0/+ 8/8 296.3±12.1
Ngsk Prnp0/0 0/5 >600
Ngsk Prnp0/0 
(112-wk p.i.)
Ngsk Prnp0/0 0/5 >600
Ngsk Prnp0/0 0/5 >600
 
DISCUSSION 
 
In the present study, we first showed that 
Ngsk Prnp0/+ mice expressing PrPLP/Dpl 
ectopically in neurons succumbed to the 
disease after the infection of a Fukuoka-1 
prion with incubation periods identical to that 
of Zrch I Prnp0/+ mice expressing no 
PrPLP/Dpl. PrPSc was similarly accumulated 
in the brains of both lines of Prnp0/+ mice, 
and pathological changes such as vacuolation 
and astrocyte infiltration patterns were 
indistinguishable between them. These 
findings are consistent with the results 
reported previously by Moore et al. (Moore 
et al., 2001) and Tuzi et al. (Tuzi et al., 2002), 
indicating that PrPLP/Dpl has no potential to 
affect the pathogenesis of prion disease. By 
contrast, Ngsk Prnp0/0 mice were free of the 
disease for up to 600 days p.i. with no 
accumulation of PrPSc in the brains after 
inoculation of the prion, confirming that PrPC 
is crucial for the pathogenesis of the diseases 
via its conversion into PrPSc. 
The pathogenesis of prion diseases is yet to 
be elucidated. Prnp0/0 mice were shown to 
spontaneously develop neurological 
abnormalities similar to those often observed 
in prion diseases, including impairment of 
memory and learning, alteration of circadian 
rhythms, and demyelination in the spinal 
cord and peripheral nerves (Collinge et al., 
1994, Nishida et al., 1999, Tobler et al., 
1996), strongly suggesting that the functional 
loss of PrPC is involved in the pathogenesis 
of the diseases at least in part. Unlike the 
accumulation of PrPSc, the constitutive 
conversion of PrPC into PrPSc is thought to 
cause the reduction of PrPC in the affected 
brain, which in turn might lead to the 
functional impairment of PrPC.  It was 
recently shown that PrPLP/Dpl ectopically 
expressed in neurons impairs the function of 
PrPC, causing neuronal cell death, 
particularly in Purkinje cells, granule cells, 
and hippocampal pyramidal cells (Anderson 
et al., 2004, Moore et al., 2001, Yamaguchi et 
al., 2004). In the present study, no 
exacerbation of prion pathogenesis was 
demonstrated in Ngsk Prnp0/+ mice 
expressing PrPLP/Dpl in neurons as 
compared with Zrch I Prnp0/+ mice 
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expressing no PrPLP/Dpl. This result seems 
to refute the idea that some aspects of the 
prion pathogenesis are attributable to the 
functional loss of PrPC. We cannot, however, 
rule out the possibility that PrPC is 
functionally inactivated in prion diseases in a 
way different from that of PrPLP/Dpl. 
 
We next showed that, in contrast to PrPSc 
abundantly accumulated in the brains of the 
diseased Ngsk Prnp0/+ mice, no PK-resistant 
PrPLP/Dpl could be detected in the brains of 
these mice nor in the Ngsk Prnp0/0 mice 
sacrificed at 360 days p.i. These results were 
consistent with those of Tuzi et al. (Tuzi et al., 
2002). We further showed that intracerebral 
inoculation of the brain homogenates of the 
diseased Ngsk Prnp0/+ mice resulted in the 
disease only in mice expressing PrPC, such as 
wild-type and Ngsk Prnp0/+ mice, but not in 
Ngsk Prnp0/0 mice which express PrPLP/Dpl 
but are devoid of PrPC. Similarly, no 
disease-specific symptoms were detected in 
indicator Ngsk Prnp0/0 mice, which were 
intracerebrally inoculated with the brain 
homogenates of the Ngsk Prnp0/0 mice 
sacrificed at 112 weeks p.i..  The 
homologous combination of PrPC and PrPSc 
is important for the efficient transmission of 
prions. Thus, taken together with the finding 
that PK-resistant PrPLP/Dpl were undetected 
in the diseased Ngsk Prnp0/+ mice and the 
Ngsk Prnp0/0 mice sacrificed at 360 days p.i., 
this unsuccessful transmission of the disease 
from these mice into Ngsk Prnp0/0 mice 
strongly indicates that PrPLP/Dpl does not 
undergo pathogenic conversion to a 
prion-like infectious protein. On the contrary, 
the disease transmission is dependent on the 
expression of PrPC in the recipient mice and 
the presence of PrPSc in the inocula, 
reaffirming the central role of PrP in prion 
diseases. 
 
Behrens et al. previously showed that 
PrPLP/Dpl is not indispensable to either the 
pathogenesis or the PrPSc generation by 
demonstrating that scrapie prions induced 
typical features of prion pathology including 
PrPSc accumulation in neuronal grafts derived 
from embryonic stem cells homozygous for a 
disrupted Prnd (Behrens et al., 2001). 
PrPLP/Dpl is the first identified host protein 
exhibiting high similarities in amino acid 
composition and protein conformation to PrP. 
No other PrP-like proteins have been 
reported to date. Together with these results, 
our findings strongly indicate that prion 
diseases are disorders specifically associated 
with the pathogenic conformation of PrP. 
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